


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Xiong et al.

Serial No. 10/509,972

Filed: October 1, 2004

For: COMPOUNDS USEFUL IN THE TREATMENT OF
ANTHRAX AND INHIBITIONG LETHAL FACTORArt Unit: To be AssignedExaminer: To be AssignedCommissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.


3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.


4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By

 Date 2/14/05

**INFORMATION DISCLOSURE STATEMENT**

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

By: Sylvia A. Ayler

Attorney _____ For Applicant(s)

Reg. No. 36,436

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-4909

Date: February 14, 2005

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc., 09/05/2003


Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number 10/509,972
 Filing Date October 1, 2004
 First Named Inventor Xiong et al.
 Group Art Unit To be Assigned
 Examiner Name To be Assigned
 Attorney Docket Number 21111YP



Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

Examiner Initials*	Cite No.	
	6.	J. M. Clements et al., "Antibacterial Activities and Characterization of Novel Inhibitors of LpxC", 2002, pp. 1793-1799, Vol. 46, No. 6, Antimicrobial Agents and Chemotherapy.
	7.	D. P. Becker et al., "Alpha-Amino-Beta-Sulphone Hydroxamates as Potent MMP-13 Inhibitors that Spare MMP-1", pp. 2719-2722, Vol. 11, Bioorganic Y Medicinal Chemistry Letters.
	8.	T. C. Dixon et al., "Anthrax", 1999, pp. 815-820, Vol. 341, No. 11, Medical Progress.
	9.	M. Mock et al., "Anthrax", 2001, pp. 647-71, Vol. 55, Annu. Rev. Microbiol.
	10.	G. Vitale et al., "Anthrax Lethal Factor Cleaves the N-Terminus of MAPKKs and Induces Tyrosine/Threonine Phosphorylation of MAPKs in Cultured Macrophages", 1998, pp. 706-11, Vol. 248, Biochemical and Biophysical Research Communications.
	11.	G. Vitale et al., "Susceptibility of Mitogen-Activated Protein Kinase Kinase Family Members to Proteolysis by Anthrax Lethal Factor", 2000, pp.739-745, Vol. 352, Biochem. J.
	12.	D. J. Weber et al., "In Vitro Susceptibility of Bacillus spp. to Selected Antimicrobial Agents", 1988, pp.642-645, Vol. 32, No. 5, Antimicrobial Agents and Chemotherapy.
	13.	E. Helgason et al., "Bacillus Anthracis, Bacillus Cereus, and Bacillus Thuringiensis-One Species on the Basis of Genetic Evidence", 2000, pp. 2627-2630, Vol. 66, No. 6, Applied and Environmental Microbiology.
	14.	N. S. Duesbery et al. "Proteolytic Inactivation of MAP-Kinase-Kinase by Anthrax Lethal Factor" 1998, pp. 734-737, Vol. 280, Science.
	15.	S. E. Hammond et al., "Lethal Factor Active-Site Mutations Affect Catalytic Activity in Vitro", 1998, pp. 2374-2378, Vol. 66, No. 5, Infection and Immunity.
	16.	R. T. Cummings et al., "Peptide-based fluorescence Resonance Energy Transfer Assay for Bacillus Anthracis Lethal Factor Protease", 2002, pp. 6603-6606, Vol. 99, No. 10, PNAS.
	17.	M. Doganay et al., "Antimicrobial Susceptibility of Bacillus Anthracis" 1991, pp. 333-335, Vol. 23, Scand J. Infect Dis.

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 SEND TO Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003